Study of efficacy of spray dried lactobacillus reuteri for helicobacter pylori infection treatment

The present study was conducted to study the effectiveness of spray dried Lactobacillus reuteri in treatment of Helicobacter pylori infection at a tertiary healthcare institute. We evaluated the compliance and outcome of spray dried Lactobacillus reuteri in the treatment of patients with Helicobacter pylori. In our study, we included patients who were positive for Helicobacter pylori on Rapid Urease test. We assessed Rapid urease test findings on follow up visit among the study subjects and observed that 63.64% study subjects reported Helicobacter pylori negative after treatment with spray dried Lactobacillus reuteri. The study showed that majority of the study subjects were females (54.55%), whereas 45.45% subjects were males, M:F ratio in the current study was 1:1.2. and the mean age of the study subjects was 41.61 ± 10.84 years. 54.55% study subjects belonged to rural area, whereas 45.45% subjects belonged to urban area. Our study’s results are comparable and similar to the other studies which show that Lactobacillus reuteri (Probiotics) are useful in the Helicobacter pylori infection treatment

Study of Efficacy of Spray Dried Lactobacillus Reuteri for Helicobacter Pylori Infection Treatment

The present study was conducted to study the effectiveness of spray dried Lactobacillus reuteri in treatment of Helicobacter pylori infection at a tertiary healthcare institute. We evaluated the compliance and outcome of spray dried Lactobacillus reuteri in the treatment of patients with Helicobacter pylori. In our study, we included patients who were positive for Helicobacter pylori on Rapid Urease test. We assessed Rapid urease test findings on follow up visit among the study subjects and observed that 63.64% study subjects reported Helicobacter pylori negative after treatment with spray dried Lactobacillus reuteri. The study showed that majority of the study subjects were females (54.55%), whereas 45.45% subjects were males, M:F ratio in the current study was 1:1.2. and the mean age of the study subjects was 41.61 ± 10.84 years. 54.55% study subjects belonged to rural area, whereas 45.45% subjects belonged to urban area. Our study's results are comparable and similar to the other studies which show that Lactobacillus reuteri (Probiotics) are useful in the Helicobacter pylori infection treatment

Traditional herbal remedies with a multifunctional therapeutic approach as an implication in COVID-19 associated co-infections

Co-infection in patients with viral infection as a predisposing factor is less focused on during epidemic outbreaks, resulting in increased morbidity and mortality. Recent studies showed that patients with coronavirus disease 2019 (COVID-19) often have both bacterial and fungal co-infections. In this study, sputum samples of 120 OPD (outdoor patients) suffering from respiratory tract infection (RTI) but negative for tuberculosis infection were collected with informed consent. Morphological, biochemical, and resistance criteria were used to classify isolates and to distinguish multidrug resistant (MDR) isolates, which were further classified on a molecular basis. We found that the isolates, including MDR strains, showed remarkable sensitivity against acetone and methanol extracts of Moringa oleifera, Adhatoda vasica, and Cassia fistula. The results strongly confirmed that multifactorial infections can produce MDR characteristics against antimicrobial drugs, which gave insight into the use of herbal drugs with their age-old traditional importance as having antiviral, antibacterial, antifungal, anti-inflammatory, and immunomodulatory effects. We conclude that apart from this, the anti-infective potential of these plants can be used in the future in the form of products such as cosmetics, pharmaceutical coatings, surface coatings, drug delivery vehicle coatings, and other bioengineered coatings for public use. Future studies are required to assess therapeutics for co-infective resistant strains and nosocomial infections with immune-enhancing effects, thereby promoting their function in holistic treatment and therapy of COVID-19 patients

COMPARATIVE STUDY OF 0.5% BUPIVACAINE AND 0.5% BUPIVACAINE WITH DEXMEDETOMIDINE FOR SPINAL ANAESTHESIA

Spinal anaesthesia remains one of the basic methods in the arsenal of modern aesthetics, which has diminished its prevalence over the last 100 years since its introduction into clinical practise. Stop physiological and metabolic changes that alleviate the discomfort of general anaesthesia during surgery. As the optimum condition for surgery is given. The purpose of this study was to evaluate the effects of dexmedetomidine added to hyperbaric bupivacaine for spinal anesthesia. The design of our study consisted of 75 patients, aged 18 to 50, undergoing ASA physical condition I, II spinal anesthesia undergoing elective lower limb orthopedic surgery, who were randomly assigned three after taking informed consent was divided into groups. The addition of dexmedetomidine to 0.5 per cent of hyperbaric bupivacaine in spinal anaesthesia greatly decreases onset time, prolonging the duration of both sensory and motor blockade

Artificial Intelligence and Machine Learning in Computational Nanotoxicology: Unlocking and Empowering Nanomedicine

Advances in nanomedicine, coupled with novel methods of creating advanced materials at the nanoscale, have opened new perspectives for the development of healthcare and medical products. Special attention must be paid toward safe design approaches for nanomaterial-based products. Recently, artificial intelligence (AI) and machine learning (ML) gifted the computational tool for enhancing and improving the simulation and modeling process for nanotoxicology and nanotherapeutics. In particular, the correlation of in vitro generated pharmacokinetics and pharmacodynamics to in vivo application scenarios is an important step toward the development of safe nanomedicinal products. This review portrays how in vitro and in vivo datasets are used in in silico models to unlock and empower nanomedicine. Physiologically based pharmacokinetic (PBPK) modeling and absorption, distribution, metabolism, and excretion (ADME)-based in silico methods along with dosimetry models as a focus area for nanomedicine are mainly described. The computational OMICS, colloidal particle determination, and algorithms to establish dosimetry for inhalation toxicology, and quantitative structure–activity relationships at nanoscale (nano-QSAR) are revisited. The challenges and opportunities facing the blind spots in nanotoxicology in this computationally dominated era are highlighted as the future to accelerate nanomedicine clinical translation